Thrombophilia Screening: Little Role for the JAK2V617F Mutation
Authors:
- Pier Mannuccio MannucciPMPier Mannuccio Mannucci
- Flora PeyvandiFPFlora Peyvandi
- 1 April 2008
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 83 (4) , 398-399
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive PatientsMayo Clinic Proceedings, 2008
- Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolismJournal of Thrombosis and Haemostasis, 2008
- Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settingsJournal of Medical Genetics, 2007
- The V617F mutation of JAK2 is very uncommon in patients with thrombosisHaematologica, 2007
- Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation statusBlood, 2006
- Leukocytosis as a major thrombotic risk factor in patients with polycythemia veraBlood, 2006
- JAK2V617F: prevalence in a large Chinese hospital populationBlood, 2006
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia veraExperimental Hematology, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005